- €14.09bn
- €14.09bn
- €1.89bn
Finland's Orion Q3 sales rise 28%; upgrades 2026 outlook
Bayer, Orion gain after positive data on prostate cancer drug Nubeqa
Europe Research Roundup: Avio, Genmab, Veolia
Europe Research Roundup: Avio, Genmab, Kerry Group
Brief: Orion Upgrades Full-Year Outlook For 2026
Brief: Orion Pharma Announces Agreement With Qilu Pharma Europe
Brief: Orion Completes Share Acquisitions
Brief: Tenax Therapeutics Phase 3 Level Trial Misses Primary Endpoint
Finnish drug developer Orion's Q2 sales rise, lifts FY outlook
Brief: Orion Q2 Pretax Profit At EUR 175.8 Mln
India's Shilpa Medicare rises after unit enters agreement with Orion Corporation
Brief: Orion Pharma Announces Deal With Shilpa Medicare For Nivolumab Biosimilar
Brief: Orion Pharma's ODM-212 Gets Orphan Designation From European Commission
Brief: Orion Animal Health Gets FDA Approval For Tessie
Orion slips as Q1 falls short of expectations
Finland's Orion Q1 net sales rise on Nubeqa growth
Brief: Orion Q1 Oper. Profit Up At EUR 114.8 Million
Brief: Orion Pharma's ODM-212 Granted Orphan Drug Designation In Mesothelioma
Orion bottoms Helsinki blue chip index on Q4 profit miss